# A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

> **NCT07722767** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 90 (estimated)

## Conditions studied

- AML (Acute Myeloid Leukemia)

## Interventions

- **DRUG:** CLN-049
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07722767
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-15
- **Primary completion:** 2027-09-30
- **Final completion:** 2030-08-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722767, "A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*